Biomerieux S A Unsp/Adr (BMXXY) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the BioMario Half-Year 2026 Financial Performance Call. Please note this webcast is being recorded, and for the first part, participants' lines will be in listen-only mode. You will have the opportunity to ask questions at the end of the presentation. This can be done by pressing pound key 5 on your telephone keypad. I will now hand the conference over to Americ Fichet, Head of Investor Relations. Thank you, hello everyone, good afternoon and thank you for joining this call. I am with Pierre Boulud, CEO, together with Guillaume Bouhours, CFO. Please note that this conference call will include forward-looking statements that may change or be modified due to uncertainties and risks related to the company's environment. Accordingly, we cannot give any assurance as to whether we will achieve these objectives. I also remind you that today's call is being recorded and that the replay will be available on our website www.biomérieux-finance.com I will now hand the call over to Pierre and then we will open the call to questions. Pierre? Hello everyone, good afternoon. So a couple of words on the agenda first. I will first of all share a few highlights on the business The first half of the year. Then I'll head over to Guillaume, who will go into more details around the financial performance and 2026 outlook. And I'll finish the call with a few words on ambitions for 2027 and 2028. So you've heard the disclaimers from Aymeric. Moving on, on the H1 highlights. So as you've seen, we are reporting a sales growth that accelerated in Q2, plus 5%, 7.3% excluding respiratory panel sales. That is compensating a lower Q1, that was at 3.9% of decline, significantly impacted by the low respiratory epidemiology. Our SEBIT at the end of H1 declined by 5% organically, re...